Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Investor Presentation – Entitlement Offer

Tuesday, October 31, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced an investor presentation regarding its entitlement offer. The company is making strides in its clinical programs, including the initiation of a Phase 1/2a study for BetaBart (RV-01). Additionally, it has received IND approval from the US FDA to begin a therapeutic clinical study targeting B7H3.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics is advancing its clinical programs.
  • The company has received IND approval from the US FDA.
  • Positive updates have been shared across multiple programs.

Full Press Release Details

• Announcements
• October 31, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• October 19, 2022
• Announcements
• October 2, 2024
• Announcements
• December 9, 2022
• Announcements
• February 23, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of Radiopharm's investor presentation?

The presentation focuses on the entitlement offer and updates on clinical programs.

What recent FDA approval did Radiopharm receive?

Radiopharm received IND approval to initiate a Phase 1 therapeutic study for BetaBart.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic candidate being studied in a Phase 1/2a clinical trial.

What updates were shared about Radiopharm's clinical programs?

Radiopharm provided positive updates across four clinical programs during the presentation.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm BetaBart Phase 1/2a FDA approval clinical study
Last updated: Oct 31, 2023